This activity focuses on improving clinician awareness and knowledge of LAG-3-based immunotherapy in metastatic melanoma. We aim to identify patients with metastatic melanoma who can benefit from LAG-3/PD-1 combination therapy and enhance the competence of the multidisciplinary team in managing these patients.
Optimizing First-Line Immunotherapy for Recurrent or Metastatic HNSCC
Overcoming Barriers to Equitable Care in HNSCC
Managing Immune-Related Adverse Events With Immunotherapies
Improving Outcomes and Addressing Racial Disparities in Patients With HR+/HER2- Early Breast Cancer: A Case-Based Learning Lab
ACC 2024: SHASTA-2 Final Study Results
ACC 2024: VOYAGER PAD Part 2
Understanding CIAS: What Does Current Literature Say About the Etiology and Pathophysiology of CIAS?
Glycine's Role in Driving the Cognitive Symptoms of CIAS
CIAS Effects on Patients and Caregivers: What Is the Personal and Economic Burden Caused by CIAS?
Tools of the Trade: Measurement-Based Care for CIAS
Unraveling the Overlapping Negative and Cognitive Symptoms in Schizophrenia
Limitations of the Current Therapeutics Used to Manage CIAS
How do you apply cognitive remediation in CIAS?
Integration Is the Key to Success: How Will the New SCZ Therapies Fit Into Clinical Treatment Paradigms?
Staying Current: What Do Recent Clinical Trial Data Say About the New and Emerging Treatment Options for CIAS?
ACC 2024: The PIONEER AF-PCI Trial
Not All Therapy Needs to Be Swallowed or Injected: The Future of Digital Therapeutics to Alleviate the Negative Symptoms of Schizophrenia
ACC 2024: VOYAGER PAD Part 1
ACC 2024: What's Really New in Electrophysiology That Will Change My Practice?
Making the Case for Dual Ang-2/VEGF-A Inhibition: Anatomical Benefits
Create your
podcast in
minutes
It is Free
RenaissanceOnlineRadio.com
Men in Lead Aprons
Denver Underground
Exercise: Learn To Love (Or At Least Like) It
NASACast Video